Editorial: Evasion of the body snatchers

Implant Dentistry

Volumn 18, Issue 5, 2009, Pages 371-372

  Marx, Robert E ^a  

^a Implant Dentistry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

DRUG INDUSTRY; EDITORIAL; ETHICS; HUMAN; JAW OSTEONECROSIS; SOCIAL BEHAVIOR;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG INDUSTRY; HUMANS; SOCIAL RESPONSIBILITY;

EID: 77949300008     PISSN: 10566163     EISSN: None     Source Type: Journal    
DOI: 10.1097/ID.0b013e3181b4aee8     Document Type: Editorial

References (8)

1. Edwards BJ, Gounder M, McKay, et al. Pharmaco-vigilance and reporting oversight in US FDA Fast Track process bisphosphonates and osteonecrosis of the jaw. Lancet Oncol. 2008;9:1166-1172.
2. American Association of Oral and Maxillofacial Surgeons Position Paper on bisphosphonate-related osteo-necrosis of the jaws. J Oral Maxillofacial Surg. 2007;65: 369-376.
3. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis. An American Academy of Oral Medicine Position Paper. J Am Dent Assoc. 2005; 136:1658-1668.
4. Koshla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaws: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22: 1479-1491.
5. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteone-crosis of the jaws: A case-control study. J Oral Maxillofac Surg. 2008;66:625-631.
6. American Dental Association Council on Scientific Affairs. Dental management of patients receiving oral bisphosphonate therapy: Expert panel recommendations. J Am Dent Assoc. 2006;137:1144-1150.
7. Ficarra A, Beninati F, Ruburro I, et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonate treatment. J Clin Periodontol. 2005;32: 1123-1128.
8. Marx RE. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61: 1115-1117.